HQY Quote, Financials, Valuation and Earnings

Schrodinger has a net margin of 8.46% compared to HealthEquity's net margin of -45.54%. HealthEquity's return on equity of 4.59% beat Schrodinger's return on equity of -38.87%.

HealthEquity has a consensus price target of $110.93, signalling upside risk potential of 29.18%. On the other hand Schrodinger has an analysts' consensus of $31.78 which suggests that it could grow by 20.14%. Given that HealthEquity has higher upside potential than Schrodinger, analysts believe HealthEquity is more attractive than Schrodinger.

HealthEquity has a beta of 0.487, which suggesting that the stock is 51.287% less volatile than S&P 500. In comparison Schrodinger has a beta of 1.773, suggesting its more volatile than the S&P 500 by 77.334%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

HealthEquity quarterly revenues are $311.8M, which are larger than Schrodinger quarterly revenues of $88.3M. HealthEquity's net income of $26.4M is higher than Schrodinger's net income of -$40.2M. Notably, HealthEquity's price-to-earnings ratio is 78.78x while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.35x versus 9.26x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

Simulations Plus has a net margin of 8.46% compared to HealthEquity's net margin of 13.7%. HealthEquity's return on equity of 4.59% beat Simulations Plus's return on equity of 3.97%.

HealthEquity has a consensus price target of $110.93, signalling upside risk potential of 29.18%. On the other hand Simulations Plus has an analysts' consensus of $46.60 which suggests that it could grow by 31.27%. Given that Simulations Plus has higher upside potential than HealthEquity, analysts believe Simulations Plus is more attractive than HealthEquity.

HealthEquity has a beta of 0.487, which suggesting that the stock is 51.287% less volatile than S&P 500. In comparison Simulations Plus has a beta of 1.130, suggesting its more volatile than the S&P 500 by 13.009%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Simulations Plus offers a yield of 0.68% to investors and pays a quarterly dividend of $0.06 per share. HealthEquity pays -- of its earnings as a dividend. Simulations Plus pays out 48.18% of its earnings as a dividend. Simulations Plus's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

HealthEquity quarterly revenues are $311.8M, which are larger than Simulations Plus quarterly revenues of $22.4M. HealthEquity's net income of $26.4M is higher than Simulations Plus's net income of $3.1M. Notably, HealthEquity's price-to-earnings ratio is 78.78x while Simulations Plus's PE ratio is 101.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.35x versus 9.17x for Simulations Plus. Usually stocks with elevated PS ratios are considered overvalued.

Veeva Systems has a net margin of 8.46% compared to HealthEquity's net margin of 27.14%. HealthEquity's return on equity of 4.59% beat Veeva Systems's return on equity of 13.71%.

HealthEquity has a consensus price target of $110.93, signalling upside risk potential of 29.18%. On the other hand Veeva Systems has an analysts' consensus of $261.98 which suggests that it could grow by 15.13%. Given that HealthEquity has higher upside potential than Veeva Systems, analysts believe HealthEquity is more attractive than Veeva Systems.

HealthEquity has a beta of 0.487, which suggesting that the stock is 51.287% less volatile than S&P 500. In comparison Veeva Systems has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.881%.

HealthEquity has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veeva Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. HealthEquity pays -- of its earnings as a dividend. Veeva Systems pays out -- of its earnings as a dividend.

HealthEquity quarterly revenues are $311.8M, which are smaller than Veeva Systems quarterly revenues of $720.9M. HealthEquity's net income of $26.4M is lower than Veeva Systems's net income of $195.6M. Notably, HealthEquity's price-to-earnings ratio is 78.78x while Veeva Systems's PE ratio is 52.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for HealthEquity is 6.35x versus 13.68x for Veeva Systems. Usually stocks with elevated PS ratios are considered overvalued.